Northeastern University

Pharmaceutical Industry Fellowships

The School of Pharmacy at Northeastern University offers a variety of two-year post-PharmD research fellowships. With the rich biopharmaceutical landscape of greater Boston and Cambridge, MA as a backdrop, our programs offer the fellow the opportunity to work with innovative industry partners in a variety of specialty areas, while partnering with Northeastern University faculty in the areas of research, scholarship, and teaching.


Enroll here to stay connected with Northeastern fellowship news.

Fellowship partners

.

Alnylam Northeastern Fellowship
Amryt Logo
Apellis Logo (1)
Blueprintmedicines Northeastern Fellowship
Bridgebio
1 CSLSeqirus CMYK Highres M01
Deciphera Northeastern Fellowship
DyneLogo
Flatiron Horizontal RGB
GSK Logo
IPSEN Northeastern Fellowship
Pacira+logo
Logo Praxis
Takeda Northeastern Fellowship
Vertex Northeastern Fellowship
X4

Specialty Areas

Clinical Development

Specialty area offered by:

  • Alnylam
Clinical Pharmacology

Specialty area offered by:

  • Vertex
Clinical Scientist

Specialty area offered by:

  • Blueprint
  • Vertex
Commercial Oncology

Specialty area offered by:

  • GSK
Commercial Operations

Specialty area offered by:

  • IPSEN
Marketing/ Marketed Product Development

Specialty area offered by:

  • Alnylam
  • Takeda
Marketing/ Marketed Product Development

Specialty area offered by:

  • Alnylam
  • Takeda
Marketing/ Marketed Product Development

Specialty area offered by:

  • Alnylam
  • Takeda
Medical Affairs

Specialty area offered by:

  • Alnylam
  • Amryt
  • Apellis
  • Blueprint Medicines
  • IPSEN
  • Praxis
  • Seqirus
  • Takeda
  • Vertex
Medical Information

Specialty area offered by:

  • Alnylam
  • IPSEN
  • GSK Oncology
  • Pacira
  • CSL Seqirus
Medical Publications / Medical Writing

Specialty area offered by:

  • Alnylam
  • Vertex
Pharmacovigilance / Patient Safety

Specialty area offered by:

  • Alnylam
  • Blueprint
  • Vertex
Regulatory Affairs

Specialty area offered by:

  • Alnylam
  • Blueprint Medicines
  • IPSEN
  • Praxis
  • Vertex
Scientific Communication

Specialty area offered by:

  • GSK
Value and Evidence Strategy (VESt)

Specialty area offered by:

  • Alnylam

Fellowship Opportunities

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, Northeastern University, in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for Fellowships no earlier than December 7th, 2022.

The AIFA is comprised of Keck Graduate Institute (KGI), Massachusetts College of Pharmacy and Health Sciences (MCPHS), Northeastern, Purdue University College of Pharmacy, Rutgers Institute for Pharmaceutical Industry Fellowships (RPIF), Saint Joseph’s University, University of North Carolina Division of Pharmacotherapy and Experimental Therapeutics (UNC, DPET), and University of Southern California School of Pharmacy (USC School of Pharmacy).

We see this respect for candidate choice as a common aspect of each of our Program’s cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline.

Click Here to view the 2023-25 Northeastern University Fellowship Recruitment Timeline

Northeastern University’s Pharmaceutical Industry Fellowship program positions are now available for candidates to apply.

Northeastern Focus

Learn

Pursue graduate degrees or certificates in Regulatory Affairs, Business, Public Health, & more – at no cost.  Learn more.

Research

Perform research with faculty and students. Present data at conferences. Publish your findings. Generate literature

Teach

Teach pharmacy students in various small and large group classes. Earn a teaching certificate of achievement

Connect

Boston has a lot of offer, both social and professional. We take advantage of it all

Stay Connected

Keep in touch with our fellowships throughout the recruitment cycle.

Alnylam Pharmaceuticals

In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotations. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

Alnylam offers 2-year post-doc Fellowship positions in the following expertise areas: Global Medical Info, Global Medical Publications, VESt/HEOR, Clinical Development, Global Market Access, Global Patient Safety and Risk Management, Regulatory Affairs, US Marketing, US Medical Affairs.

AMRYT

Amryt is a global commercial-stage biopharmaceutical company dedicated to developing and delivering innovative new treatments to help improve the lives of patients with rare and debilitating diseases. A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity, and ethical practice. Our exceptional team offers a wealth of experience in identifying, commercializing, and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals and get our life changing medicines to all those who need them.

Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt’s commercial business comprises three orphan disease products – metreleptin (Myalept®/ Myalepta®); octreotide (Mycapssa®); and lomitapide (Juxtapid®/ Lojuxta®). Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE®) technology platform.

Amryt offers a 2-year post-doc Fellowship position in the following expertise area: Medical Affairs.

Apellis

The mission at Apellis is to boldly deliver revolutionary therapies for people living with serious diseases by harnessing complement, the foundational part of the human immune system. Vision: A leader in the biotech industry known for compassion, revolutionary science, and contributions to humankind around the world. Apellis is committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3.

Apellis offers a 2-year post-doc Fellowship position in the following expertise area: Global Medical Affairs.

*Partnership under development*

Blueprint Medicines

Blueprint Medicines offers a 2-year Fellowship Program in collaboration with Northeastern University designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Blueprint Medicines is a global precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines.

Blueprint Medicines offers 2-year post-doc Fellowship positions in the following expertise areas: Global Medical Affairs, Regulatory Affairs, Clinical Scientist, Drug Safety/Pharmacovigilance.

BridgeBio /Eidos Therapeutics

BridgeBio /Eidos Therapeutics offers a 2-year Fellowship Program in collaboration with Northeastern University designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Bridgebio /Eidos mission is to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Our Focus is to create the opportunity to help patients with genetic disease is vast. There are more than 8,000 diseases caused by a single genetic mutation. In total they affect tens of millions of people, but less than 50 FDA approved therapies exist to treat this class of conditions. By capitalizing on scientific advancements that deepen our understanding of genetic diseases, we have the potential to develop breakthrough medicines for patients in need at an unprecedented scale.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs.

Eidos Therapeutics/BridgeBio Pharma is not recruiting for the 2023-25 Fellowship cohort, please check in next year.

CSL Seqirus

Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.

Our vision is a world protected from influenza.

CSL Seqirus offers a 2-year post-doc Fellowship position in the following expertise area: Medical Affairs.

Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. Fueled by our proprietary drug discovery platform, Deciphera’s mission is to discover, develop, and deliver important new medicines to patients for the treatment of cancer. We aim to provide novel treatments for patients through inhibition of protein kinases.

In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, and the United Kingdom.

Deciphera (NASDAQ: DCPH) is a publicly traded company headquartered in Waltham, Massachusetts. Our state-of-the-art research facility is located in Lawrence, Kansas.

We offer an outstanding culture and opportunity for personal and professional growth based on our “PATHS” Core Values:
Patients – places the importance of improving the lives of patients and their caregivers at the forefront of every day’s work.
Accountability – for our performance and the way we work with coworkers and other stakeholders.
Transparency – in our intent and actions to both internal and external stakeholders.
Honesty and Integrity – fosters trust and strives to deliver on our and the company’s promises.
Stewardship – values and uses wisely the resources and investments provided to the company.

One Mission, Inspired by Patients: Defeat Cancer.TM At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer – and that passion for making a difference extends to the patient groups and communities in which we live and work.

Deciphera is not recruiting for the 2023-25 Fellowship cohort, please check in next year.

Dyne Therapeutics

We are fearless innovators united by a shared mission: To bring transformative therapies to people living with serious muscle diseases. We pursue our goals with passion, determination, agility and urgency, recognizing that countless lives are depending on our efforts. We are here to forever change lives. We know we will deliver.

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Dyne Therapeutics is not recruiting for the 2023-25 Fellowship cohort, please check in next year.

Flatiron Health, Inc

Flatiron Health, Inc.Ⓡ is a healthtech company founded in 2012 and is a world leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in care and treatments for patients with cancer. We translate patient experiences into real-world evidence (RWE) to improve treatment, inform policy, and advance research. Our unparalleled network supports physicians and other healthcare professionals on the cancer frontlines, and can connect clinical practices and patients directly to research that can expand and improve treatment and care options in oncology.

We are a mission- and values-driven company dedicated to building a workforce that reflects the diversity of those impacted by cancer. Our organization consists of more than 2,500 software engineers, data scientists, biostatisticians, epidemiologists, health professionals and other experts who joined Flatiron to learn from the experiences of people with cancer – and to translate that knowledge into better outcomes for patients.

Flatiron Health, Inc is not recruiting for the 2023-25 Fellowship cohort, please check in next year.

GSK

GSK is a global biopharma company with the ambition and purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

Cross-therapeutic area rotations will be offered as part of the Global Medical Information fellowship. The Global Scientific Communications fellowship will only focus on oncology assets.

GSK offers 2-year post-doc Fellowship positions in the following expertise areas: Global Medical Info and Scientific Communications.

IPSEN

Ipsen Biopharmaceuticals, Inc. is launching a 2-year post-PharmD fellowship in U.S. Medical Affairs in collaboration with Northeastern University, School of Pharmacy.

Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.

Ipsen offers 2-year post-doc Fellowship positions in the following expertise areas: US Medical Affairs/Regulatory Affairs and Commercial Oncology.

Pacira

Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes. Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.

Pacira offers a 2-year post-doc Fellowship position in the following expertise area: Global Medical Information.

Praxis

Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system (“CNS”) disorders characterized by neuronal imbalance.

At Praxis we get things done. Praxis is the process of using a theory or something that you have learned in a practical way. It is a mindset that allows us to simplify the complex and independently define a solution without being restricted by predefined processes.

Praxis offers a 2-year post-doc Fellowship position in the following expertise area: Regulatory Affairs/Medical Affairs.

*Partnership under development*

Takeda

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

Takeda offers 2-year post-doc Fellowship positions in the following expertise areas: Medical Affairs and Marketed Product Development.

Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

Vertex offers 2-year post-doc Fellowship positions in the following expertise areas: Clinical Pharmacology/Modeling Simulation, Medical Affairs, Regulatory Affairs, Safety, and Clinical Scientist.

X4

Developing novel therapeutics to treat people with rare immune system disorders

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system via antagonism of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. We believe that inhibition of the CXCR4 receptor creates the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Our lead clinical candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. We are currently evaluating the safety and efficacy of mavorixafor in a Phase 3 clinical trial for the treatment of patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. To date, mavorixafor has demonstrated proof-of-concept in WHIM syndrome in a Phase 2 clinical trial, including clinically meaningful increases in neutrophil and lymphocyte biomarker counts, as well as a trend of reduction in infection rates and wart burden, and has been generally well tolerated. Enrollment in the Phase 3 WHIM clinical trial is now complete and top-line clinical results are expected in the fourth quarter of 2022. For the WHIM indication, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Designation in the U.S., and Orphan Drug Status in both the U.S. and European Union.

We are also studying mavorixafor in two Phase 1b clinical trials – one in combination with ibrutinib in patients with a rare B-cell lymphoma called Waldenstrom macroglobulinemia, and the other as a monotherapy in patients with Severe Congenital Neutropenia (SCN) and other chronic neutropenia disorders.

X4 is a global company headquartered in Boston, Massachusetts with research offices based in Vienna, Austria.At X4 our mission is to develop treatments that have a clear and profound impact for patients suffering with rare diseases, including primary immunodeficiencies (such as WHIM syndrome) and cancer. We are developing potential new treatments through a rigorous R&D process for diseases where we believe we can dramatically improve the overall health of patients. Yet, we know that developing innovative, new medicines is highly challenging. So, as a fundamental part of our values, we seek to bring grit to all of our efforts. Our core values define us and act as guideposts for our thoughts, behaviors and decisions every day.

X4 is not recruiting for the 2023-25 cohort, please check in next year.